Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | -5.73% | |
Upper Bollinger Band Touch | Strength | -5.73% | |
Stochastic Sell Signal | Bearish | 4.87% | |
NR7 | Range Contraction | 4.87% | |
Overbought Stochastic | Strength | 4.87% | |
Gapped Down | Weakness | 4.87% | |
Bearish Engulfing | Bearish | 2.29% |
Alert | Time |
---|---|
Possible NR7 | about 10 hours ago |
Possible Inside Day | about 10 hours ago |
60 Minute Opening Range Breakdown | about 13 hours ago |
Down 3% | about 13 hours ago |
Down 2 % | about 14 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
- Earnings date: 03/10/2025
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.775 |
52 Week Low | 4.6 |
Average Volume | 1,186,483 |
200-Day Moving Average | 10.58 |
50-Day Moving Average | 6.89 |
20-Day Moving Average | 5.80 |
10-Day Moving Average | 6.18 |
Average True Range | 0.52 |
RSI (14) | 50.50 |
ADX | 18.28 |
+DI | 23.33 |
-DI | 16.15 |
Chandelier Exit (Long, 3 ATRs) | 5.15 |
Chandelier Exit (Short, 3 ATRs) | 6.15 |
Upper Bollinger Bands | 6.72 |
Lower Bollinger Band | 4.88 |
Percent B (%b) | 0.74 |
BandWidth | 31.63 |
MACD Line | -0.09 |
MACD Signal Line | -0.26 |
MACD Histogram | 0.1711 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.85 | ||||
Resistance 3 (R3) | 6.91 | 6.77 | 6.75 | ||
Resistance 2 (R2) | 6.77 | 6.62 | 6.74 | 6.72 | |
Resistance 1 (R1) | 6.51 | 6.52 | 6.44 | 6.45 | 6.68 |
Pivot Point | 6.37 | 6.37 | 6.34 | 6.34 | 6.37 |
Support 1 (S1) | 6.11 | 6.22 | 6.04 | 6.05 | 5.82 |
Support 2 (S2) | 5.97 | 6.12 | 5.94 | 5.78 | |
Support 3 (S3) | 5.71 | 5.97 | 5.75 | ||
Support 4 (S4) | 5.65 |